Seagen

Subsidiary of Pfizer (PFE) · United States

Assets

(5 total)
5Total Assets
2Approved
2Phase 3 / Filed
1Phase 1–2 / Early
6Diseases
Quick filter:
Showing 5 of 5 assets
Target & Modality
Approved
Anti-CD30 antibody-drug conjugateAntibody–drug conjugate
Non-Small Cell Lung CancerDiffuse Large B-Cell LymphomaNon-Hodgkin LymphomaCutaneous T-Cell Lymphoma
Large B-Cell Lymphoma, Peripheral T-Cell Lymphoma, High-Grade B-Cell Lymphoma
Approved
Tissue Factor (TF)Antibody–drug conjugate
Non-Small Cell Lung CancerCervical Cancer
Phase 3
PD-L1Antibody–drug conjugate
Non-Small Cell Lung Cancer
Phase 3
Integrin beta-6 (ITGB6)Antibody–drug conjugate
Non-Small Cell Lung Cancer
Phase 1
CEACAM5Antibody–drug conjugate
Non-Small Cell Lung CancerColorectal Cancer

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
March 2028 (1)
Fetrastobart vedotinPhase 3Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma
Est. primary completion 2028-03-10 · NCT07144280 · CT.gov ↗
What to watch
2029 (1)
March 2029 (1)
Fetrastobart vedotinPhase 1/2Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer
Est. primary completion 2029-03-08 · NCT07227298 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 June 2026ApprovalTisotumab Vedotin Humax-tf-adcNMPA approves TIVDAK for recurrent or metastatic cervical cancer
CN, NMPA · Source ↗
1 September 2025ApprovalTisotumab Vedotin Humax-tf-adcTIVDAK approved in Hong Kong
HK, Hong Kong Department of Health · Source ↗

Financial reports

No financial reports recorded.